查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
卡斯尔曼氏病治疗的全球市场 - 2022-2029
市场调查报告书
商品编码
1004982

卡斯尔曼氏病治疗的全球市场 - 2022-2029

Global Castleman Disease Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

研究机构进行的卡斯尔曼病治疗临床试验预计将推动市场增长。

卡斯尔曼氏病协作网络 (CDCN) 与宾夕法尼亚大学和阿肯色大学医学院合作，与研究药物西罗莫司合作，用于治疗对抗 IL 无反应的特发性多中心 卡斯尔曼氏病 (iMCD) 成人-6 疗法。正在进行测试。西妥昔单抗 (Silvant) 和托珠单抗是两种抗 IL-6 药物 (Actemra)。此外，中国北京的北京协和医院正在招募参与者进行一项临床试验，以测试硼替佐米、环磷□胺和地塞米松（BCD 方案）的有效性和安全性。因此，上述声明预计将在预测期内推动市场。

约束

由于该疾病的低流行率和对该疾病的了解不足，人们的意识低下。在预测期内，预计几家公司的治疗成本上升和专利到期将阻碍市场。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。 siltoximab 和 tocilizumab 等抗 IL6 药物也用于治疗一些危重患者的 COVID-19 诱导的细胞因子风暴。此外，siltoximab 和 tocilizumab 等抗 IL6 药物现已被确定为一些特发性多中心 卡斯尔曼氏病患者的有效治疗方法。这些药物可以短期缓解症状，但也很安全，可以长期控制那些有反应的人。在 COVID-19 大流行期间，CDCN 了解 siltoximab 和 tocilizumab 的短缺情况。 CDCN 担心这些重要药物对 卡斯尔曼氏病患者的可用性。 CDCN获悉，siltoximab和tocilizumab的生产商已承诺为卡斯尔曼氏病患者提供药物。因此，许多公司转移到其他地区以确保产品可用性并保护其供应链。这样一来，市场受到了影响，但随着经济活动的恢復，预计将获得动力。

全球城堡疾病治疗市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按诊断划分的市场细分
  • 按处理方法划分的市场细分
  • 最终用户的市场细分
  • 市场细分:按分销渠道
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 研究机构治疗卡斯尔曼病的临床试验预计将推动市场增长。
    • 限制
      • 预计飙升的处理成本将阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 单核卡斯尔曼氏病
  • 多中心卡斯尔曼氏病

第8章诊断

  • 验血/验尿
  • 图像检查
    • X 射线检测
    • CT 扫描
    • 其他
  • 淋巴结活检
  • 其他

第 9 章治疗

  • 免疫疗法
    • 西妥昔单抗（思万特）
    • 利妥昔单抗（利妥昔单抗）
    • 其他
  • 化疗
  • 皮质类固醇
    • 泼尼松
    • 托珠单抗
    • 来那度胺
    • 糖皮质激素
    • 其他
  • 抗病毒剂
    • 更昔洛韦
    • 其他

第 10 章，最终用户

  • 医院
  • 诊所
  • 门诊手术中心
  • 诊断中心
  • 其他

第 11 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 14 章公司简介

  • EUSA 製药
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Johnson & Johnson Services, Inc.
  • Genentech USA, Inc.
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Par Pharmaceutical
  • Exela Pharma Sciences

第15章 卡斯尔曼氏病治疗的全球市场-DataM

简介目录
Product Code: DMPH3381

Market Overview

The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.

Market Dynamics

Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.

The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market

The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global castleman disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8-associated multicentric Castleman disease (HHV-8-associated MCD), and 1000 are HHV-8-negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.

EUSA Pharma:

Overview:

EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.

­Product Portfolio:

SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.

Why Purchase the Report?

Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Unicentric Castleman disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multicentric Castleman disease

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Blood and urine tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. X-rays
    • 8.3.2. CT Scans
    • 8.3.3. Others
  • 8.4. Lymph node biopsy
  • 8.5. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Immunotherapy*
    • 9.2.1. Siltuximab (Sylvant)
    • 9.2.2. Rituximab (Rituxan)
    • 9.2.3. Others
    • 9.2.4. Introduction
    • 9.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Chemotherapy
  • 9.4. Corticosteroids
    • 9.4.1. Prednisone
    • 9.4.2. Tocilizumab
    • 9.4.3. Lenalidomide
    • 9.4.4. Glucocorticoids
    • 9.4.5. Others
  • 9.5. Antiviral drugs
    • 9.5.1. Ganciclovir
    • 9.5.2. Others

10. By End user

    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. EUSA Pharma*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Johnson & Johnson Services, Inc.
  • 14.3. Genentech USA, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. Amgen Inc.
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. Par Pharmaceutical
  • 14.8. Exela Pharma Sciences

LIST NOT EXHAUSTIVE

15. Global Castleman Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us